Showing results (351-360 of 831) with videos related to
Sort By:
Pageof 84
Nature Reviews. Disease Primers|January 20, 2017
Chronic lymphocytic leukaemiaThomas J Kipps, Freda K Stevenson, Catherine J Wu, et al.Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Pregnancy among patients with chronic myeloid leukemia treated with imatinibPatricia Ault, Hagop Kantarjian, Susan O'Brien, et al.Cancer|November 30, 2006
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcomeHagop M Kantarjian, Susan O'Brien, Jianqin Shan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phaseJorge E Cortes, Dan Jones, Susan O'Brien, et al.Cancer|December 18, 2008
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimensDushyant Verma, Susan O'Brien, Deborah Thomas, et al.Leukemia Research|August 22, 2008
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemiaChen-Hsiung Yeh, Richard Tseng, Zhong Zhang, et al.Cancer|July 22, 2014
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemiaPreetesh Jain, Hun Ju Lee, Wei Qiao, et al.Leukemia & Lymphoma|August 15, 2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxideAlireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, et al.Pageof 84